Deuterated Iridium Complexes for OLED Lifetime

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current organic light-emitting devices (OLEDs) face challenges in achieving long device lifetime and commercial viability due to limitations in emissive layer performance, particularly in terms of stability and efficiency.

Innovation Solution

The use of heteroleptic iridium compounds with specific ligand structures, including partially or fully deuterated alkyl groups, as emissive or non-emissive dopants in the organic emissive layer, which enhance the stability and performance of OLEDs by improving the lifetime of the devices.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Duration of action of stationary object

If conventional organic emissive materials are used in OLEDs, then the device can be fabricated with cost advantages and flexibility, but the device lifetime and stability are limited

Engineering Contradiction:
Improvedevice lifetimeVSAvoidemissive layer stability
Core Design Contradiction:
Duration of action of stationary objectVSReliability

Solution Approach 1:

The patent applies parameter changes by substituting hydrogen atoms with deuterium atoms in the alkyl groups of the iridium complex ligands. This isotopic substitution changes the physical and chemical parameters of the emissive material, resulting in enhanced photostability and reduced degradation rates, thereby extending device lifetime while maintaining reliability

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent employs composite materials by combining deuterated alkyl groups with specific ligand structures (combinations of N^N and N^C ligands) around the iridium center. This creates a composite emissive material with synergistic properties that simultaneously improve stability, efficiency, and lifetime of the OLED device

Inventive Principle:
Principle #40Composite materials

2Reliability

If the emissive layer performance is improved to achieve long device lifetime, then commercial viability increases, but the complexity of material synthesis and characterization increases

Engineering Contradiction:
Improveemissive layer performanceVSAvoidmaterial synthesis complexity
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The patent applies segmentation by dividing the ligand structure into distinct functional components: deuterated alkyl groups for stability enhancement, N^N ligands for photophysical properties, and N^C ligands for structural support. This modular approach allows independent optimization of each component and simplifies the overall synthesis strategy

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The patent applies local quality by selectively deuterating only the alkyl groups in specific positions of the ligand structure rather than the entire molecule. This targeted approach enhances stability where needed while minimizing the complexity of full molecular deuteration, balancing performance improvement with synthesis feasibility

Inventive Principle:
Principle #3Local quality

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The implementation of heteroleptic iridium compounds with deuterated alkyl groups leads to improved OLED device lifetime and makes them more suitable for commercial applications by maintaining efficiency and stability, as demonstrated by extended device performance compared to non-deuterated counterparts.

Implementation Method 1

One application for phosphorescent emissive molecules is a full color display

Methodology Applied
Scientific EffectPhosphorescence: Phosphorescence

Data Source

PatentEP3882254B1Phosphorescent homoleptic tris-[deuterated-2(2-pyridinyl)phenyl]-iridium complexes for use in light-emitting devices
Publication Date: 2023.10.04 UNIVERSAL DISPLAY CORP
  • EP3882254B1 patent drawingFigure 1
  • EP3882254B1 patent drawingFigure 2
  • EP3882254B1 patent drawingFigure 3~4

AI summary

Metal iridium complexes, devices containing the same, and formulations including the same described. The complexes can have the formula Ir(L1)n(L2)3-n, wherein the first ligand L1 has Formula I, the second ligand L2 has Formula II, L1 is different from L2; R1 is a partially or fully deuterated group consisting of alkyl and cyloalkyl; R2 represents mono, di, tri substitutions or no substitution; R3, R4 and R5 each represent mono, di, tri, tetra substitutions or no substitution; R2 and R3are each independently selected from the group consisting of hydrogen, deuterium, alkyl, cycloalkyl, and combinations thereof; R4 and R5 are each independently selected from the group consisting of hydrogen, deuterium, halide, alkyl, cycloalkyl, heteroalkyl, arylalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carbonyl, carboxylic acids, ester, nitrile, isonitrile, sulfanyl, sulfinyl, sulfonyl, phosphino, and combinations thereof; and n is 1 or 2. Homoleptic, tris-iridium complex including deuterated alkyl groups are also described.